SpiN-Tec

SpiN-Tec is a chimeric recombinant protein vaccine developed as a booster against COVID-19. It consists of a fusion protein (SpiN) that combines the Receptor Binding Domain (RBD) of the SARS-CoV-2 Spike protein with the Nucleocapsid (N) protein. The vaccine is formulated with CTVad1, a squalene-based emulsion adjuvant similar to MF59. Unlike many first-generation COVID-19 vaccines that focus solely on the Spike protein, SpiN-Tec is designed to induce a broader and more durable immune response by targeting the more conserved Nucleocapsid protein, thereby eliciting robust T-cell immunity alongside neutralizing antibodies. This approach is intended to maintain efficacy against emerging SARS-CoV-2 variants of concern. The vaccine was developed by researchers at the Federal University of Minas Gerais (UFMG) in Brazil with support from the Ministry of Science, Technology and Innovation (MCTI).

Other names

SpiN vaccineSpiN-Tec vaccine